Stryker (SYK)
(Delayed Data from NYSE)
$332.02 USD
-2.28 (-0.68%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $332.04 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
SYK 332.02 -2.28(-0.68%)
Will SYK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SYK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SYK
Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
Here's Why You Should Retain Ensign Group (ENSG) Stock Now
SYK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
The Zacks Analyst Blog Highlights NIKE, Stryker and TJX
Top Analyst Reports for NIKE, Stryker & TJX
Other News for SYK
Stryker to announce financial results for its second quarter of fiscal year 2024
10 Health Care Stocks Whale Activity In Today's Session
Top Analyst Reports For NIKE, Stryker & TJX
Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company’s Full Potential
Dividend Champion, Contender, And Challenger Highlights: Week Of June 23